drugset
drugset / Trial / NCT06921291

Role of Salbutamol in the Management of Transient Tachypnea of the New Born

NCT06921291 ↗

Phase 1 Completed 60 enrolled Khyber Teaching Hospital
NaSingle-groupOpen-labelTreatment

Summary

Role of Salbutamol in the management of transient tachypnea of the new born

Timeline

Start
2024-08-01
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Salbutamol Unknown 0.15 mg/kg Inhaled

Indications

No indication recorded.